FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

						or Sec	tion 3	O(h) of the	Investme	nt Co	mpany Act	of 194	)								
1. Name and Address of Reporting Person* RIEFLIN WILLIAM JL						2. Issuer Name and Ticker or Trading Symbol NGM BIOPHARMACEUTICALS INC									Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director 10% Owner						
					_ N	GM	]									give title			specify		
(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year)										below)	give title		below)			
C/O NGM BIOPHARMACEUTICALS, INC.						04/05/2024															
333 OYSTER POINT BOULEVARD						4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)						
																X Form filed by One Reporting Person					
(Street)																ed by Mo	re than	One Repo	rting		
SOUTH SAN FRANCISCO CA			94080												Person						
FRANC						Rule 10b5-1(c) Transaction Indication															
(City) (State) (Zip)			(Zip)			Check this box to indicate that a transaction was made pursuant to a cont the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.								to a contra	ct, instruction	or written p	olan that	t is intended	to satisfy		
		Та	ble I - No	n-Der	ivati	ve S	ecur	ities Ac	quired	, Dis	sposed o	of, or	Ben	eficially	/ Owned						
1. Title of Security (Instr. 3) 2. Transac										3. 4. Securities Acquired (A) of									7. Nature of		
				Date (Month/Day/Y			if any	Execution Date, if any (Month/Day/Year)		Transaction Code (Instr.		Disposed Of (D) (Instr. 3, 4 a			Beneficial	ly	Form: Direct (D) or Indirect		Indirect Beneficial Ownership		
			(Mont			n/Day/Year)	8)			Τ,	<b>4</b> \		Owned Fo	-	(I) (Instr. 4)		(Instr. 4)				
									Code	٧	Amount		A) or D)	Price	Transactio						
Common Stock					/05/2024				U		5,172	2	D	(1)	0			D			
Common Stock 04/05/						7/2024													See		
					)5/202				U		2,769,168 D		D	(1)	0				footnote <sup>(2)</sup>		
			Table II -	Doriv	,ativ	. 50	curit	ios Acqu	uirod	Dien	osod of	or E	onof	icially	Ownod						
			Table II -	(e.g.,	puts	s, ca	lls, v	arrants	, optio	ns,	converti	ble s	ecur	ities)	OWITEG						
1. Title of	2.	3. Transaction	3A. Deemed 4.							6. Date Exercisable and 7. Title and Amo					8. Price of	9. Numb			11. Nature		
Derivative Security	Conversion or Exercise	Date (Month/Day/Year)	Execution I if any	· 1	Transa Code (				Expiration Date (Month/Day/Year)			of Securities Underlying		6	Derivative Security	derivative Securities		Ownership Form:	of Indirec Beneficia		
(Instr. 3)	Price of Derivative		(Month/Day	r/Year)	8)							Derivative Securit (Instr. 3 and 4)			(Instr. 5)	Beneficially Owned Following Reported		Direct (D) or Indirect			
	Security																	(I) (Instr. 4	)		
				ľ										Amount	1	Transaction(s (Instr. 4)					
									Date		Expiration		i	or Number							
					Code	٧	(A)	(D)	Exercisa	ble	Date	Title	- (	of Shares							
Stock Option	\$3.69 <sup>(3)(4)</sup>	04/05/2024			D			78,407	(3)(4)		05/09/2033	Com	non	78,407	(3)(4)	0		D			
(Right to Buy)	\$3.09	04/03/2024			D			78,407	(2)(1)		03/09/2033	Sto	k	70,407	(3)(1)			"			
Stock										$\dashv$			$\dashv$								
Option (Right to	\$15.2 <sup>(3)(4)</sup>	04/05/2024			D			80,000	(3)(4)		03/02/2032	Com		80,000	(3)(4)	0		D			
Buy)												510									
Stock																					
Option (Right to	\$31.93 <sup>(3)(4)</sup>	04/05/2024			D			80,000	(3)(4)		03/16/2031	Com		80,000	(3)(4)	0		D			
Buy)							_			_			_			1					
Stock Option	216 47(3)(4)	04/05/2024			D			75,000	(3)(4)		02/02/2020	Com	non	75.000	(3)(4)						
(Right to Buy)	\$16.47 <sup>(3)(4)</sup>	04/05/2024			ע			/3,000	(2)(4)		02/03/2030	Sto		75,000	(-)(-)	0		D	1		
Stock				$\dashv$			+			$\dashv$			+		<del>                                     </del>				+		
Option	\$12.06 <sup>(3)(4)</sup>	04/05/2024			D			50,000	(3)(4)		02/06/2029	Com		50,000	(3)(4)	0		D	1		
(Right to Buy)	<u></u>		<u> </u>			L		<u> </u>		[		5100	·K		<u> </u>	L_		L_			
Stock				$\neg$						$\neg$											
Option (Right to	\$8.14 <sup>(3)(4)</sup>	04/05/2024			D			225,000	(3)(4)		01/30/2028	Com		225,000	(3)(4)	0		D	1		

## **Explanation of Responses:**

Buy)

- 1. Disposed of pursuant to a Rollover Agreement between, inter alia, Mr. Rieflin, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc. a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for shares in Parent
- 2. Shares held by Rieflin Family Trust U/A 4/3/00.
- 3. This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Parent and Purchaser, dated as of February 25, 2024 ("Merger 3. This Point's extended to the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than \$1.55 per share (the "Offer Price") (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes,
- 4. (Continued from footnote 3) equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.

/s/ Valerie Pierce, Attorney-in-

04/05/2024

Fact

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.